Product descriptionPyrimethamine is a diaminopyrimidine which is structurally related to trimethoprim. It is effective against erythrocytic stage of Plasmodium (P) falciparum and less so against P. vivax, P. ovale and P. malariae. Pyrimethamine also inhibits the sporogony in the mosquito, resulting in a decrease of transmission of the infection within the community
[1].
The mechanism of action of pyrimethamine is related to its inhibition of dihydrofolic reductase necessary for the folic acid synthesis in the parasite. Pyrimethamine acts slowly and is not recommended as monotherapy for acute malaria attacks. Resistance to pyrimethamine developed soon when the drug was used on a large scale as monoprophylaxis
[1]. In resistant strains, the enzyme dihydrofolic reductase binds to pyrimethamine several hundred times less than in sensitive strains
[2]. This high grade resistance is probably a onestep mutation and cannot be overcome by increasing the dose. However, when combined with long-acting sulphonomides (sulphadoxine), the effect of pyrimethamine is potentiated and the risk of developing resistant strains is far less.
ApplicationFor the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine.
Pyrimethamine is a dihydrofolate reductase inhibitor, like the biguanides, and is structurally related to trimethoprim. It is seldom used alone. Pyrimethamine in fixed combinations with dapsone or sulfadoxine is used for treatment and prophylaxis of chloroquine-resistant falciparum malaria. The synergistic activities of pyrimethamine and sulfonamides are similar to those of trimethoprim/sulfonamide combinations. Resistant strains of Plasmodium falciparum have appeared world wide. Prophylaxis against falciparum malaria with pyrimethamine alone is therefore not recommended. Most strains of Plasmodium vivax have remained sensitive. Pyrimethamine is also used in combination with a sulfonamide for the treatment of Toxoplasmosis. It is slowly absorbed from the gastrointestinal tract with peak plasma levels 4-6 hours after dosing. Pyrimethamine is bound to plasma proteins and is extensively metabolized before excretion. Its elimination half-life is 3-5 days.
Package25kg/drum
SpecificationItem name | Standard |
Characteristics | White or off white powder |
Identification | Positive |
Clarity and color of solution | 2.5% W/V mixed solution is clear; color≤BY6 |
Acidity and alkalinity | Requires 0.01M sodium hydroxide VS not more than 0.2ml and 0.01M hydrochloric acid VS not more than 0.4ml |
Related substances | Any second spot in solution 1.0% W/V is not more than 0.25% |
Sulphate | ≤80ppm |
Melting point | 238-242ºC |
Loss on drying | ≤0.50% |
Ash | ≤0.1% |
Assay(on dry basis) | 99.0-101.0% |
![Pyrimethamine USP Good Quality Competitive Price](//image.made-in-china.com/226f3j00kKAUiTHjfVov/Pyrimethamine-USP-Good-Quality-Competitive-Price.webp)
![Pyrimethamine USP Good Quality Competitive Price](//image.made-in-china.com/226f3j00kKdUhuPECWbM/Pyrimethamine-USP-Good-Quality-Competitive-Price.webp)
![Pyrimethamine USP Good Quality Competitive Price](//image.made-in-china.com/226f3j00qjmRliDFMVbv/Pyrimethamine-USP-Good-Quality-Competitive-Price.webp)